What is it about?
Ustekinumab is a human monoclonal antibody selectively targeting the shared p40 subunit of interleukin-12 (IL-12) and IL-23. Its efficacy for the treatment of psoriasis has been well-documented in previous trials. We report a rare case of a patient who developed Squamous Cell Carcinoma (SCC) of the tongue after the commencement of ustekinumab as the treatment of plaque-type psoriasis.
Featured Image
Photo by Chermiti Mohamed on Unsplash
Why is it important?
To our knowledge, no link between ustekinumab and tongue SCC has been demonstrated before. Our report suggests that ustekinumab may induce the development of oral SCC in predisposed individuals.
Read the Original
This page is a summary of: Squamous Cell Carcinoma of the Tongue in a Patient on Ustekinumab as the Treatment of Psoriasis, Journal of Clinical Research in Dermatology, August 2017, Symbiosis Group,
DOI: 10.15226/2378-1726/4/3/00161.
You can read the full text:
Contributors
The following have contributed to this page
